[Oral anticoagulant therapy--renaissance of an old therapy?].
Although the antithrombotic potential of oral anticoagulants is undisputed, bleeding complications constitute a serious problem. One of the main causes for these complications has been a lack of standardization of the prothrombin time. The introduction of the International Normalized Ratio (INR) has led to a better standardization of prothrombin time. Thus, the same level of anticoagulation can be reached using different reagents and therefore over- and undercoagulation can be avoided. Furthermore, the benefit/risk ratio can be improved by adapting the intensity of anticoagulation to the indication. The following clinical conditions are established indications for treatment with oral anticoagulants: Prevention of cardiac emboli in acute anterior myocardial infarction with atrial thrombus, in patients with atrial fibrillation with or without mitral valve disease, in patients with prosthetic heart valves and in patients with dilated cardiomyopathy. Furthermore, oral anticoagulants should be given to patients after femoropopliteal bypass. A relatively mild oral anticoagulant treatment (INR 2-3) is sufficient to prevent recurrences of venous thrombosis and pulmonary emboli. The duration of treatment in patients with venous thromboembolism depends on some clinical features and the results of clotting tests which indicate an increased tendency to thrombosis.
D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001779:Blood Coagulation Factors / Q000378:metabolism; D001780:Blood Coagulation Tests; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000188:drug therapy; D014812:Vitamin K / Q000097:blood
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D014812:Vitamin K
Orale Antikoagulantientherapie--Renaissance einer alten Therapie?